- Hematopoietic stem cell engineering at a crossroads
[作者：Riviere, I; Dunbar, CE; Sadelain, M,期刊：Blood, 页码：1107-1116 , 文章类型： Review，,卷期：2012年119-5]
- The genetic engineering of hematopoietic stem cells is the basis for potentially treating a large array of hereditary and acquired diseases, and stands as the paradigm for stem cell engineering in general. Recent clinica...
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
[作者：Madan, S; Kumar, SK; Dispenzieri, A; Lacy, MQ; Hayman, SR; Buadi, FK; Dingli, D; Rajkumar, SV; Hogan, WJ; Leung, N; Grogan, M; Gertz, MA,期刊：Blood, 页码：1117-1122 , 文章类型： Article，,卷期：2012年119-5]
- High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement. We studie...
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
[作者：Kantarjian, HM; Shah, NP; Cortes, JE; Baccarani, M; Agarwal, MB; Undurraga, MS; Wang, JX; Ipina, JJK; Kim, DW; Ogura, M; Pavlovsky, C; Junghanss, C; Milone, JH; Nicolini, FE; Robak, T; Van Droogenbroeck, J; Vellenga, E; Bradley-Garelik, MB; Zhu, C; Hochhaus, A,期刊：Blood, 页码：1123-1129 , 文章类型： Article，,卷期：2012年119-5]
- Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagn...
- Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation
[作者：Chen, Y; Kornblit, B; Hamlin, DK; Sale, GE; Santos, EB; Wilbur, DS; Storer, BE; Storb, R; Sandmaier, BM,期刊：Blood, 页码：1130-1138 , 文章类型： Article，,卷期：2012年119-5]
- To reduce toxicity associated with external gamma-beam radiation, we investigated radioimmunotherapy with an anti-CD45 mAb labeled with the alpha-emitter, astatine-211 (At-211), as a conditioning regimen in dog leukocyte...
|